NASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis $3.64 -0.05 (-1.36%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.61▼$3.7450-Day Range$2.16▼$3.6952-Week Range$1.94▼$3.81Volume28,008 shsAverage Volume49,860 shsMarket Capitalization$155.57 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get DiaMedica Therapeutics alerts: Email Address DiaMedica Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside92.3% Upside$7.00 Price TargetShort InterestHealthy0.41% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingAcquiring Shares$3 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.63) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector639th out of 936 stocksPharmaceutical Preparations Industry295th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDiaMedica Therapeutics has received no research coverage in the past 90 days.Read more about DiaMedica Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.41% of the outstanding shares of DiaMedica Therapeutics have been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DiaMedica Therapeutics has recently increased by 10.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMAC. Previous Next 1.9 News and Social Media Coverage News SentimentDiaMedica Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DiaMedica Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for DMAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.12% of the stock of DiaMedica Therapeutics is held by institutions.Read more about DiaMedica Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.63) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about DiaMedica Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About DiaMedica Therapeutics Stock (NASDAQ:DMAC)DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More DMAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMAC Stock News HeadlinesJuly 2, 2024 | insidertrades.comKoch Thomas Von Purchases 1,200,000 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) StockJune 26, 2024 | businesswire.comDiaMedica Therapeutics Announces $11.8 Million Private PlacementJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 26, 2024 | businesswire.comDiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into PreeclampsiaMay 14, 2024 | investing.comDiaMedica Therapeutics Inc (DMAC)May 13, 2024 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comDMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 8, 2024 | finance.yahoo.comDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial ResultsMay 2, 2024 | finance.yahoo.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 2, 2024 | businesswire.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 1, 2024 | finance.yahoo.comBullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of StockApril 17, 2024 | businesswire.comDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeMarch 25, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 22, 2024 | seekingalpha.comDiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | investorplace.comDMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023See More Headlines Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DMAC CUSIPN/A CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+92.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.21% Return on Assets-34.45% Debt Debt-to-Equity RatioN/A Current Ratio18.14 Quick Ratio18.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book2.70Miscellaneous Outstanding Shares42,740,000Free Float39,665,000Market Cap$155.57 million OptionableOptionable Beta1.49 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Dietrich John Pauls MBA (Age 53)President, CEO & Director Comp: $818.61kMr. Scott Kellen CPA (Age 59)CFO & Corporate Secretary Comp: $485.43kDr. Kirsten L. Gruis M.D. (Age 51)M.S., Independent Consultant Comp: $449.29kDr. Ambarish Shah Ph.D.Chief Technology OfficerMr. Dominic R. Cundari (Age 73)Chief Commercial Officer Mr. David J. Wambeke (Age 40)Chief Business Officer Dr. Lorianne K. Masuoka M.D. (Age 63)Chief Medical Officer More ExecutivesKey CompetitorsZevra TherapeuticsNASDAQ:KMPHAlumisNASDAQ:ALMSTerns PharmaceuticalsNASDAQ:TERNEntrada TherapeuticsNASDAQ:TRDAMereo BioPharma GroupNASDAQ:MREOView All CompetitorsInsiders & InstitutionsKoch Thomas VonBought 1,200,000 shares on 6/28/2024Total: $3 M ($2.50/share)Vanguard Group Inc.Bought 211,351 shares on 5/10/2024Ownership: 2.670%View All Insider TransactionsView All Institutional Transactions DMAC Stock Analysis - Frequently Asked Questions How have DMAC shares performed this year? DiaMedica Therapeutics' stock was trading at $2.84 on January 1st, 2024. Since then, DMAC stock has increased by 28.2% and is now trading at $3.64. View the best growth stocks for 2024 here. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. When did DiaMedica Therapeutics IPO? DiaMedica Therapeutics (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX) and Capricor Therapeutics (CAPR). This page (NASDAQ:DMAC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
